LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

Search

TransMedics Group Inc

Avatud

SektorTervishoid

130.38 -2.87

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

129.09

Max

136.06

Põhinäitajad

By Trading Economics

Sissetulek

-11M

24M

Müük

-14M

144M

P/E

Sektori keskmine

51.118

110.024

Kasumimarginaal

16.909

Töötajad

728

EBITDA

-13M

33M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+13.11% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

24. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

-78M

4.4B

Eelmine avamishind

133.25

Eelmine sulgemishind

130.38

Uudiste sentiment

By Acuity

50%

50%

165 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

TransMedics Group Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2025, 19:15 UTC

Suurimad hinnamuutused turgudel

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Võrdlus sarnastega

Hinnamuutus

TransMedics Group Inc Prognoos

Hinnasiht

By TipRanks

13.11% tõus

12 kuu keskmine prognoos

Keskmine 146.86 USD  13.11%

Kõrge 170 USD

Madal 115 USD

Põhineb 8 Wall Streeti analüütiku instrumendi TransMedics Group Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

6

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

92.43 / 94.18Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

165 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat